EcoDrugPlus

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSJJAG00000019820
Gene Symbol: PSMB5
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSJJAG00000013428
Gene Symbol: PSMB6
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSJJAG00000020212
Gene Symbol: PSMB7
2 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSJJAG00000023598
Gene Symbol: PSMB8
3 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSJJAG00000022884
Gene Symbol: PSMB9
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSJJAG00000006163
Gene Symbol: PSMC1
3 Cross references
204 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSJJAG00000021354
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSJJAG00000013476
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSJJAG00000015828
Gene Symbol: PSMC5
3 Cross references
225 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSJJAG00000010940
Gene Symbol: PSMC6
3 Cross references
241 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSJJAG00000016565
Gene Symbol: PSMD1
2 Cross references
209 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSJJAG00000015236
Gene Symbol: PSMD11
3 Cross references
283 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).